The present invention relates to a new crystalline modification of 6-(4-chlorophenyl)-2,2-dmethyl-7-phenyl-2, S-dihydro-1H-pyrrolizin-S-ylacetic acid which is referred to as polymorph B. It has a peak in the solid state
13
C-NMR spectrum (with adamantane as external reference standard; CH group d=29.45 ppm) in the range from 179.8 to 180.2 ppm and can be processed directly to a pharmaceutical formulation.
本发明涉及6-(4-
氯苯基)-2,2-二甲基-7-苯基-2, S-二氢-1H-
吡啶嗪-5-
乙酸的新晶体多形B。它在固态13C-NMR光谱中具有峰值(以
金刚烷作为外部参考标准;CH基d=29.45 ppm),范围在179.8至180.2 ppm之间,并可直接加工成制药配方。